EUVIMEDEUVIMED entdecken
Crossref

NSF evaluation of gadolinium biodistribution in renally impaired rats: Using novel metabolic Gd2O3 nanoparticles coated with β-cyclodextrin (Gd2O3@PCD) in MR molecular imaging

Hanieh Ashouri, Nader Riyahi Alam, Mehdi Khoobi, Soheila Haghgoo, Zahra Rasouli, Mahdi Gholami

Magnetic Resonance Imaging · 2024

DOI: 10.1016/j.mri.2024.01.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Magnetic Resonance Imaging, 2024. Verfasst von Hanieh Ashouri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Sciences(TUMS), Tehran, Iran. Hauptthemen laut MEDLINE: Nephrogenic Fibrosing Dermopathy, Renal Insufficiency, beta-Cyclodextrins, Nanoparticles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Tehran University of Medical Sciences and Health Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of conventional gadolinium(Gd)-based contrast agents in magnetic resonance imaging (MRI) poses a significant risk of Nephrogenic Systemic Fibrosis (NSF) syndrome in patients with impaired renal function (grades 4 and 5). To address this issue, a new study has introduced a novel metabolic Gadolinium oxide nanoparticle (Gd2O3 NPs) coated with β-cyclodextrin (βCD). The study aims to investigate NSF syndrome by quantifying tissue Gd deposition biodistribution in renal impairment rats using MR molecular imaging. This is the first study of its kind to use this approach. A group of 20 rats were divided into four groups, each containing five rats that underwent 5/6 nephrectomy. The rats received 12 intravenous injections of a novel homemade synthesized gadolinium oxide polycyclodextrin (Gd2O3@PCD) at a dose of 0.1 mmol/kg, conventional contrast agents (CAs) drugs of Omniscan (Gd-DTPA-BMA) and Dotarem (Gd-DOTA), at a dose of 2.5 mmol/kg, and 250 μl saline for two injections per week during six weeks. T1-weighted MR imaging was performed before the injections and once a week for six weeks to quantify Gd deposition in four different organs (skin, liver, heart, and lung) in rats using inductively coupled plasma mass spectrometry (ICP-MS). The relationship between Signal-to-Noise Ratio (SNR) and biodistribution of Gd deposition due to NSF-induced syndrome was also calculated. The results of the study showed that the Gd concentrations in tissues were significantly higher in the Gd2O3@PCD group compared to the other groups, without any significant histopathological changes (P < 0.05). In the Gd2O3@PCD group, Gd was mainly deposited in the skin, followed by the liver, lung, and heart, without any symptoms of thickening or hardening of the skin. The Gd concentrations in the skin, liver, lung, and heart were significantly lower in the Dotarem group than in the Omniscan group (P < 0.05). In the histopathological examinations, the Omniscan group showed increased cellularity in the dermis. A significant hyperintensity was observed in the Gd2O3@PCD-treated rats compared to the Dotarem and Omniscan groups in the liver, heart, and lung. Compared to conventional Gd-based CAs, the novel metabolically Gd2O3@PCD with increased SNR, biosafety, and a considerably lower probability of developing NSF, has potential applicability for diagnosing patients with renal diseases in clinical MR Molecular Imaging (MRMI).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nephrogenic Fibrosing DermopathyRenal Insufficiencybeta-CyclodextrinsNanoparticlesMeglumineOrganometallic CompoundsHumansRatsAnimalsContrast MediaGadoliniumRats, WistarTissue DistributionGadolinium DTPAMagnetic Resonance ImagingMolecular Imaging

Stichwörter der Autor:innen

Gd2O3@PCDMagnetic resonance molecular imagingMorphological and metabolic contrast agentNSF

Substanzen

gadodiamidegadoterate meglumineContrast Mediagadolinium oxideGadoliniumGadolinium DTPAbeta-CyclodextrinsMeglumineOrganometallic Compounds

Autor:innen und Institutionen

  • Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Sciences(TUMS), Tehran, Iran.
  • Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Sciences(TUMS), Tehran, Iran; Concordia University, Perform Center, Montreal, Quebec, Canada; Biomaterials Group…
  • Biomaterials Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran; Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Te…
  • Pharmaceutical Department, Food & Drug Laboratory Research Center, Ministry of Health, Tehran, Iran.
  • Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Sciences(TUMS), Tehran, Iran; Medical Imaging Center, Motahari Hospital, Jahrom University of Medical Sciences (…
  • Department of Toxicology and Pharmacology, Toxicology and Poisoning Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Förderung

  • Tehran University of Medical Sciences and Health Services

Zitieren

APA

Ashouri, H., Riyahi Alam, N., Khoobi, M., Haghgoo, S., Rasouli, Z., & Gholami, M. (2024). NSF evaluation of gadolinium biodistribution in renally impaired rats: Using novel metabolic Gd2O3 nanoparticles coated with β-cyclodextrin (Gd2O3@PCD) in MR molecular imaging. Magnetic Resonance Imaging. https://doi.org/10.1016/j.mri.2024.01.003

Vancouver

Ashouri H, Riyahi Alam N, Khoobi M, Haghgoo S, Rasouli Z, Gholami M. NSF evaluation of gadolinium biodistribution in renally impaired rats: Using novel metabolic Gd2O3 nanoparticles coated with β-cyclodextrin (Gd2O3@PCD) in MR molecular imaging. Magnetic Resonance Imaging. 2024. doi:10.1016/j.mri.2024.01.003

BibTeX
@article{Ashouri2024,
  author = {Ashouri, Hanieh and Riyahi Alam, Nader and Khoobi, Mehdi and Haghgoo, Soheila and Rasouli, Zahra and Gholami, Mahdi},
  title = {NSF evaluation of gadolinium biodistribution in renally impaired rats: Using novel metabolic Gd2O3 nanoparticles coated with β-cyclodextrin (Gd2O3@PCD) in MR molecular imaging},
  journal = {Magnetic Resonance Imaging},
  year = {2024},
  doi = {10.1016/j.mri.2024.01.003}
}
Kostenlos starten →